Trial Profile
Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary) ; Moclobemide (Primary)
- Indications Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders
- Focus Therapeutic Use
- 15 Mar 2018 Status changed from active, no longer recruiting to discontinued as all participants finished the trial.
- 10 Jan 2017 New trial record